Multiple myeloma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 4
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• AMPK 0
• B7-H3 0
• NRAS 1
• TIGIT 0
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Sweden· EU contribution €2,000,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation (MicroMM)

  Technische Universitaet Muenchen· Muenchen, Germany· EU contribution €1,466,571· until Oct 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY (iN-KEY)

  Banc de Sang I Teixits· Barcelona, Spain· EU contribution €9,998,178· until Sept 2031· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT (CERTAINTY)

  Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev· Munchen, Germany· EU contribution €9,999,253· until May 2028· 8 countries

5 of 7 running projects, newest first. Listed amounts together: €35.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

  NCT04150965· Multiple Myeloma Research Consortium· Updated 14 Feb 2025

  “Pharmaceutical support has been discontinued.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• Clinical manifestations and cardiac abnormalities in systemic Amyloid A Amyloidosis.

  Int J Cardiol, Oct 2026

• Association between oral ulcerative lesions, oral infections, and fever during the pre-engraftment phase after hematopoietic cell transplantation: results from the Orastem study.

  Support Care Cancer, Oct 2026

• Beta Testing an mHealth Symptom Management Intervention for People With Advanced Cancer: Single-Cohort Feasibility and Acceptability Study.

  JMIR Cancer, Sept 2026

• Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.

  Hematology, Sept 2026

• The impact of pomalidomide-containing induction on stem cell mobilization and engraftment in multiple myeloma: a single-center experience.

  Ann Hematol, Aug 2026

• Plasma Exchange in Myeloma-Associated Acute Kidney Injury: A Multicenter Propensity-Matched Cohort Study.

  J Clin Apher, Aug 2026

• Cancer risk in patients with nontuberculous mycobacterial pulmonary disease: a nationwide population-based cohort study.

  Respir Res, Jul 2026

• A nested case-control study of monoclonal gammopathy of undetermined significance in the Multiethnic Cohort study.

  Blood Adv, Jul 2026

• Plerixafor Plus G-CSF Versus Etoposide Combined With Cyclophosphamide and G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Single Center Observational Propensity Score-Matched Cohort Study.

  J Clin Apher, Jun 2026

• Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia.

  Leuk Res, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.